We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Phathom Pharmaceuticals Inc
1 own
4 watching
Current Price
$11.76
$0.04
(0.34%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
487.67M
52-Week High
14.447
52-Week Low
5.84
Average Volume
0.71M
Dividend Yield
--
P/E Ratio
--
Market Capitalization487.67M52-Week High14.44752-Week Low5.84Average Volume0.71MDividend Yield--P/E Ratio--What does the Phathom Pharmaceuticals Inc do?
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Read More
How much money does Phathom Pharmaceuticals Inc make?
News & Events about Phathom Pharmaceuticals Inc.
Ticker Report
1month ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT Get Rating) COO Azmi Nabulsi acquired 10,000 shares of the businesss stock in a transaction that occurred on Tuesday, April 11th. The stock was bought at an average cost of $8.26 per share, for a total transaction of $82,600.00. Following the...
Zolmax
1month ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT Get Rating) COO Azmi Nabulsi acquired 10,000 shares of the businesss stock in a transaction that occurred on Tuesday, April 11th. The stock was bought at an average cost of $8.26 per share, for a total transaction of $82,600.00. Following the completion of ...
Globe Newswire
1month ago
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the ...
Zolmax
1month ago
Needham & Company LLC restated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT Get Rating) in a report published on Wednesday, Benzinga reports. The brokerage currently has a $23.00 price objective on the stock. A number of other research analysts have also weighed in on PHAT. ...
PR Newswire
1month ago
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT...
Frequently Asked Questions
Frequently Asked Questions
What is Phathom Pharmaceuticals Inc share price today?
Can Indians buy Phathom Pharmaceuticals Inc shares?
How can I buy Phathom Pharmaceuticals Inc shares from India?
Can Fractional shares of Phathom Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Phathom Pharmaceuticals Inc stocks?
What is today’s traded volume of Phathom Pharmaceuticals Inc?
What is today’s market capitalisation of Phathom Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Phathom Pharmaceuticals Inc?
What percentage is Phathom Pharmaceuticals Inc down from its 52-Week High?
What percentage is Phathom Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$11.76
$0.04
(0.34%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.